Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of pemphigus patients from RITUXIMAB3
2018-001417-32Phase 3Completed
- Sponsor
- Rouen University Hospital
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in pemphigus and Bullous Pemphigoid (BP), sponsored by Rouen University Hospital. Primary endpoint: Disease status classification. Started Jun 2018; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigusBullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2018-001417-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001417-32.